MeSH tree: C04.557.450.565.835
Synovial sarcoma is an aggressive malignant tumor that primarily affects the limbs of teenagers and young adults. While it can be cured if completely removed by surgery, recurrence or metastasis, the spread of cancer to organs ...
Feb 26, 2026
0
4
A patient with synovial sarcoma, a soft-tissue cancer that usually occurs in the large joints of the arms and legs, is the first in Arizona treated with a new immune cell therapy known as TECELRA at the HonorHealth Research ...
Dec 14, 2025
0
17
A collaborative research team, led by scientists at VCU Massey Comprehensive Cancer Center and Huntsman Cancer Institute at the University of Utah, has identified a targeted drug that could effectively treat an aggressive ...
Nov 19, 2025
0
44
In the sport of sumo, a bout most commonly ends when one competitor is pushed or thrown outside of a ring of straw bales partially buried in clay. New research shows that using a drug as a blocker to outcompete the SUMO2 ...
Sep 4, 2025
0
20
Plasma-activated medium (PAM) shows tumor-fighting effects against the rare form of cancer known as synovial sarcoma, an Osaka Metropolitan University-led research team has found.
May 1, 2025
0
19
Within the next couple of weeks, the first blood samples from patients will arrive at the loading dock of Adaptimmune, a biotechnology company headquartered on the northeastern edge of the Navy Yard.
Oct 9, 2024
0
37
The U.S. Food and Drug Administration (FDA) has granted accelerated approval for the immunotherapy afamitresgene autoleuecel (Tecelra, also known as afami-cel) for the treatment of adults with a rare soft tissue cancer called ...
Aug 5, 2024
0
51
A clinical trial led by researchers at Washington University School of Medicine in St. Louis has shown that a T cell immunotherapy—in which the patients' own T cells are genetically modified to attack and kill cancer cells—is ...
Mar 28, 2024
0
50
A new case report titled "Intrathoracic synovial sarcoma with BRAF V600E mutation" has been published in Oncotarget.
Jul 18, 2023
0
56
Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types ...
Jan 9, 2023
0
68
